- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02786810
Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
April 10, 2018 updated by: University of Tennessee
The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal ultrasound.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38013
- University of Tennessee Health Science Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 50 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent
- Age more than or equal to 8 years
- Patient with history of urinary tract infection (UTI) and history of Voiding Cystourethrogram (VCUG) for vesicoureteral reflux
- Candidate for Dimercaptosuccinic acid (DMSA) scan or scan for renal scar
- Demonstration of renal scarring by DMSA scan or renal ultrasound without contrast
Includes healthy volunteers
Exclusion Criteria:
- Age less than 8years
- Allergy to contrast or related products
- Cardiac shunt/ congenital heart anomalies
- Abnormal baseline ECG
- Open heart surgery
- Evidence of retinopathy
- Patient in intensive care
- Unable to comply with study requirement
- History of emphysema
- Unable to maintain oxygen saturation of 92% on at room air
- Pregnancy and lactation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Contrast
All subjects will be recruited into this arm.
All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.
|
Used as a contrast to enhance renal ultrasound
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visualization of Renal Scars Compared to Previous Imaging
Time Frame: 1 hour
|
The study will evaluate the contrast agent's ability to enable the ultrasound to produce adequate images of the kidneys as compared to the subject's previous renal imaging.
This outcome will be measured in percentage of scars visualized by other imaging methods that were detected by using the contrast agent.
|
1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events Related to the Study Drug.
Time Frame: 1 week
|
The study will evaluate how many people experience adverse events, specifically the two most common effects (headache and nausea), during the study or during the week following the study.
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Hains, M.D., University of Tennessee
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Actual)
November 1, 2016
Study Completion (Actual)
November 1, 2016
Study Registration Dates
First Submitted
May 17, 2016
First Submitted That Met QC Criteria
May 25, 2016
First Posted (Estimate)
June 1, 2016
Study Record Updates
Last Update Posted (Actual)
May 11, 2018
Last Update Submitted That Met QC Criteria
April 10, 2018
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1504311FB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infection
-
Gloucestershire Hospitals NHS Foundation TrustUnknownCatheter Infection | Urinary Tract Infection in Pregnancy | Urinary Tract Infection Following Delivery
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUrinary Tract Infection | Recurrent Urinary Tract InfectionCanada
-
Hadassah Medical OrganizationUnknown
-
Impatients N.V. trading as myTomorrowsInmunotek S.L.No longer availableUrinary Tract Infections | Bladder Infection | Recurrent Urinary Tract Infection | Urinary Tract Infection Bacterial | Chronic Urinary Tract InfectionCzechia, Denmark, Serbia, France, Germany, Turkey, Belgium, Finland, Luxembourg, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden
-
National Institute of Allergy and Infectious Diseases...TerminatedUrinary Tract InfectionUnited States
-
University Of PerugiaUnknownUrinary Tract Infection
-
NanovibronixShaare Zedek Medical CenterUnknownUrinary Tract InfectionIsrael
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)UnknownUrinary Tract InfectionCanada
-
Bactiguard ABRehab Station StockholmCompletedComplications; Catheter, Urinary Infection or InflammationSweden
-
University of ManitobaTerminatedComplicated Urinary InfectionCanada
Clinical Trials on Sulfur hexafluoride type-a lipid microspheres
-
Children's Hospital of PhiladelphiaBracco Diagnostics, IncRecruitingNecrotizing Enterocolitis of Newborn | Bowel IschemicUnited States
-
Children's Hospital of PhiladelphiaBracco Diagnostics, IncRecruitingHypoxic-Ischemic Encephalopathy | Brain Ischemia HypoxiaUnited States
-
Children's Hospital of PhiladelphiaCompletedCovid19 | Multisystem Inflammatory Syndrome in Children (MIS-C)United States
-
Children's Mercy Hospital Kansas CityCompleted
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingBreast CarcinomaUnited States
-
Boston Children's HospitalWithdrawn
-
Bracco Diagnostics, IncCompleted
-
Mayo ClinicActive, not recruitingLymphedema ArmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
Isaac E. HallAmerican Heart Association; National Kidney FoundationRecruiting